| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2014NatCo...5.3518F |
| P6179 | Dimensions Publication ID | 1051956689 |
| P356 | DOI | 10.1038/NCOMMS4518 |
| P932 | PMC publication ID | 4132974 |
| P698 | PubMed publication ID | 24670920 |
| P5875 | ResearchGate publication ID | 261138317 |
| P50 | author | Martin Vingron | Q1905174 |
| Peter Nürnberg | Q2077335 | ||
| Peter M Schneider | Q88044759 | ||
| Iver Petersen | Q88074401 | ||
| Sven Perner | Q89425842 | ||
| Marius Lund-Iversen | Q89880869 | ||
| Luka Ozretić | Q114291494 | ||
| Sascha Ansén | Q114291495 | ||
| Frauke Leenders | Q114291537 | ||
| Ilona Dahmen | Q114291539 | ||
| Alex Soltermann | Q114291541 | ||
| Erich Stoelben | Q114291542 | ||
| Graziella Bosco | Q114320713 | ||
| Magdalena Bogus | Q114320714 | ||
| Janine Altmüller | Q30004014 | ||
| Lynnette Fernandez-Cuesta | Q30114397 | ||
| Federico Cappuzzo | Q37392605 | ||
| Åslaug Helland | Q38155382 | ||
| John K. Field | Q42754256 | ||
| Gavin Wright | Q51543878 | ||
| Martin Peifer | Q52301181 | ||
| Lukas C Heukamp | Q56563867 | ||
| Thomas Zander | Q57083870 | ||
| Stefan Haas | Q59526355 | ||
| Ruping Sun | Q59752733 | ||
| Odd Terje Brustugun | Q66425371 | ||
| Steinar Solberg | Q66425464 | ||
| Elisabeth Brambilla | Q70964699 | ||
| Christine M. Lovly | Q82683894 | ||
| P2093 | author name string | Christian Müller | |
| Ulrich Lang | |||
| Xin Lu | |||
| Reinhard Buettner | |||
| Roman K Thomas | |||
| William D Travis | |||
| Benjamin Solomon | |||
| Jürgen Wolf | |||
| Zoe Wainer | |||
| Kathryn Konrad | |||
| Julie George | |||
| Prudence Russell | |||
| Viktor Achter | |||
| Russell Hyde | |||
| Berit Pinther | |||
| Danila Seidal | |||
| Michael Pa Davies | |||
| P2860 | cites work | Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles | Q24536351 |
| Mutational heterogeneity in cancer and the search for new cancer-associated genes | Q24606956 | ||
| Massive genomic rearrangement acquired in a single catastrophic event during cancer development | Q24631164 | ||
| Mediator and cohesin connect gene expression and chromatin architecture | Q24632695 | ||
| Fast and accurate short read alignment with Burrows-Wheeler transform | Q24653853 | ||
| Cohesin's binding to chromosomes depends on a separate complex consisting of Scc2 and Scc4 proteins | Q27939252 | ||
| Comprehensive genomic characterization of squamous cell lung cancers | Q28274701 | ||
| Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing | Q28275103 | ||
| The cohesin complex and its roles in chromosome biology | Q28302885 | ||
| Circular binary segmentation for the analysis of array-based DNA copy number data | Q29615406 | ||
| Fast and SNP-tolerant detection of complex variants and splicing in short reads | Q33751343 | ||
| ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking | Q33896155 | ||
| Memories from the polycomb group proteins. | Q34033660 | ||
| Dicer is essential for formation of the heterochromatin structure in vertebrate cells | Q34332793 | ||
| Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. | Q34342958 | ||
| PICH, a centromere-associated SNF2 family ATPase, is regulated by Plk1 and required for the spindle checkpoint | Q34600951 | ||
| Autoregulation of the nonsense-mediated mRNA decay pathway in human cells | Q35567463 | ||
| The SWI/SNF complex--chromatin and cancer. | Q35667471 | ||
| Molecular genetics of multiple endocrine neoplasia types 1 and 2. | Q36111935 | ||
| Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host | Q36257990 | ||
| Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer | Q36568988 | ||
| Menin mediates epigenetic regulation via histone H3 lysine 9 methylation | Q36890205 | ||
| Using GenePattern for gene expression analysis | Q37190539 | ||
| Menin critically links MLL proteins with LEDGF on cancer-associated target genes | Q37217351 | ||
| Nonsense-mediated mRNA decay in human cells: mechanistic insights, functions beyond quality control and the double-life of NMD factors | Q37622077 | ||
| Reprogramming human fibroblasts to neurons by recapitulating an essential microRNA-chromatin switch. | Q37633299 | ||
| SWI/SNF nucleosome remodellers and cancer. | Q37886668 | ||
| Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities. | Q38009559 | ||
| Histone lysine methylation dynamics: establishment, regulation, and biological impact | Q38064095 | ||
| Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer | Q38322114 | ||
| Understanding the words of chromatin regulation | Q42274324 | ||
| Exponential decay of GC content detected by strand-symmetric substitution rates influences the evolution of isochore structure | Q46879246 | ||
| Statistical Significance of Clustering for High-Dimension, Low–Sample Size Data | Q57529102 | ||
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3518 | |
| P577 | publication date | 2014-03-27 | |
| P1433 | published in | Nature Communications | Q573880 |
| P1476 | title | Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids | |
| P478 | volume | 5 |
| Q49721004 | A case of a primary lung cancer comprised of adenocarcinoma and atypical carcinoid tumor with both components harboring BRAF p.V600E mutation |
| Q56341375 | A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal |
| Q50318253 | A liquid biopsy for bronchopulmonary/lung carcinoid diagnosis |
| Q33946857 | A mixture of carcinoid tumors, extensive neuroendocrine proliferation, and multiple pulmonary sclerosing hemangiomas |
| Q58804394 | A quantitative method for assessing smoke associated molecular damage in lung cancers |
| Q48320507 | Biology and evolution of poorly differentiated neuroendocrine tumors |
| Q26767029 | Cellular and molecular biology of small cell lung cancer: an overview |
| Q41914832 | Changing histopathological diagnostics by genome-based tumor classification |
| Q45140096 | Classification of pulmonary neuroendocrine tumors: new insights |
| Q99555663 | Comprehensive Analysis of MEN1 Mutations and Their Role in Cancer |
| Q36883530 | Comprehensive genomic profiles of small cell lung cancer |
| Q35561180 | Driver gene mutations of non-small-cell lung cancer are rare in primary carcinoids of the lung: NGS study by ion Torrent |
| Q64997109 | Effects of KEAP1 Silencing on the Regulation of NRF2 Activity in Neuroendocrine Lung Tumors. |
| Q91216637 | Engaging chromatin: PRC2 structure meets function |
| Q38679359 | Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. |
| Q93064180 | Exploring the molecular and biological background of lung neuroendocrine tumours |
| Q26750737 | GEP- NETS UPDATE: Genetics of neuroendocrine tumors |
| Q37513931 | Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors |
| Q55523920 | Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma. |
| Q47722867 | Genetic associations with neuroendocrine tumor risk: results from a genome-wide association study. |
| Q48520101 | Genomic landscape of pancreatic neuroendocrine tumours: The International Cancer Genome Consortium |
| Q90702187 | Histopathological, immunohistochemical, genetic and molecular markers of neuroendocrine neoplasms |
| Q54117764 | Inhibiting TRK Proteins in Clinical Cancer Therapy. |
| Q55141745 | Insights into Novel Prognostic and Possible Predictive Biomarkers of Lung Neuroendocrine Tumors. |
| Q91839128 | Integrative Genomic Characterization Identifies Molecular Subtypes of Lung Carcinoids |
| Q92735048 | Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids |
| Q51763437 | Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. |
| Q41579730 | LSD1 modulates the non-canonical integrin β3 signaling pathway in non-small cell lung carcinoma cells. |
| Q90639806 | Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells |
| Q38551599 | Lung cancer: developments, concepts, and specific aspects of the new WHO classification |
| Q41981114 | Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D. |
| Q89818911 | MEN1 deficiency leads to neuroendocrine differentiation of lung cancer and disrupts the DNA damage response |
| Q47312955 | Molecular alterations of neuroendocrine tumours of the lung. |
| Q64988272 | Molecular and Morphological Profiling of Lung Cancer: A Foundation for "Next-Generation" Pathologists and Oncologists. |
| Q49875027 | Molecular challenges of neuroendocrine tumors |
| Q45360690 | Molecular strategies in the management of bronchopulmonary and thymic neuroendocrine neoplasms |
| Q89622228 | Molecular studies of lung neuroendocrine neoplasms uncover new concepts and entities |
| Q48127891 | Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm |
| Q36432090 | Mutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: a comparison of a neglected tumour group |
| Q38841735 | NETs: organ-related epigenetic derangements and potential clinical applications |
| Q38849534 | Neuroendocrine Tumors of the Urinary Bladder According to the 2016 World Health Organization Classification: Molecular and Clinical Characteristics |
| Q47116688 | Neuroendocrine tumors of the thymus and mediastinum |
| Q39934413 | Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets. |
| Q26752380 | Notch Signaling in Neuroendocrine Tumors |
| Q90614313 | Orthopedia Homeobox (OTP) in Pulmonary Neuroendocrine Tumors: The Diagnostic Value and Possible Molecular Interactions |
| Q88913402 | P53 Gene Mutation Identified by Next Generation Sequencing in Poorly Differentiated Neuroendocrine Carcinoma of the Nasal Cavity |
| Q48297055 | PBRM1 loss is a late event during the development of cholangiocarcinoma |
| Q52728727 | Pan-cancer analysis of somatic mutations across 21 neuroendocrine tumor types. |
| Q26824536 | Predictive biomarkers in precision medicine and drug development against lung cancer |
| Q26775959 | Predictive factors of response to mTOR inhibitors in neuroendocrine tumours |
| Q49505557 | Pulmonary neuroendocrine carcinomas-evidence for a spectrum of differentiation |
| Q94456902 | Pulmonary small cell carcinoma: Review, common and uncommon differentials, genomics and management |
| Q26998657 | SWI/SNF chromatin remodeling complexes and cancer |
| Q64257290 | Sclerosing pneumocytoma mixed with a typical carcinoid tumor: A case report and review of literature |
| Q36811784 | Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? |
| Q51734136 | Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes. |
| Q92688374 | Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices |
| Q91624644 | Systemic treatment for lung carcinoids: from bench to bedside |
| Q35806960 | Telomerase activation by genomic rearrangements in high-risk neuroblastoma |
| Q92533583 | The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy |
| Q49270812 | The genetic landscape of breast carcinomas with neuroendocrine differentiation |
| Q38253997 | Therapeutic biomarkers in lung neuroendocrine neoplasia. |
| Q48221145 | Thymus neuroendocrine tumors with CTNNB1 gene mutations, disarrayed ß-catenin expression, and dual intra-tumor Ki-67 labeling index compartmentalization challenge the concept of secondary high-grade neuroendocrine tumor: a paradigm shift |
| Q91934071 | Transcriptomic data helps refining classification of pulmonary carcinoid tumors with increased mitotic counts |
| Q38207553 | Unraveling tumor grading and genomic landscape in lung neuroendocrine tumors |
| Q46316777 | Update on large cell neuroendocrine carcinoma |
| Q92826192 | Updates on the Role of Molecular Alterations and NOTCH Signalling in the Development of Neuroendocrine Neoplasms |
| Q37202500 | Werner syndrome through the lens of tissue and tumour genomics. |
| Q85901877 | [Lung cancer. Developments, concepts and preview of the new WHO classification] |
| Q87015108 | [Molecular diagnostics of non-small cell lung cancer: New markers and technologies] |
| Q87530471 | [Molecular pathology of lung cancer. State of the art 2014] |
| Q85901880 | [Neuroendocrine tumors of the lungs. From small cell lung carcinoma to diffuse idiopathic pulmonary neuroendocrine cell hyperplasia] |
| Q53512514 | [Pulmonary neuroendocrine tumors in the new WHO 2015 classification: Start of breaking new grounds?]. |
| Q61447919 | iRODS metadata management for a cancer genome analysis workflow |
Search more.